Domestic players have witnessed success in rural areas of Indonesia . Due to inaccessibility and language barrier existing in the rural areas , the domestic players have been better able to bridge the gap as compared to international players . The domestic players have also dominated the Over the Counter drugs which are driven by the increasing self medication behavior of the population . Domestic players dominate the Anti-Infectives , Gastrointestinal and metabolism and respiratory therapeutic segments .
Indonesia biopharmaceutical industry is in the nascent stage . There is a strong interest from research-based global biopharma companies to conduct clinical research in Indonesia because of the large concentrated patient populations and disease profiles . Furthermore , as the industry intends to move towards self sufficiency , Indonesian government released the 11th economic stimulus package with the aim of boosting the domestic production of medicines ' raw materials , particularly for five product categories namely biotechnology , vaccines , herbal extracts , active pharmaceutical ingredients and medical devices .
In order to tap the existing potential , large domestic pharmaceutical companies have tied up with international players to manufacture biopharmaceutical products for the treatment of chronic diseases such as cancer , kidney failure and others
ProBioGen AG , a CDMO based in Germany , and Bio Farma , a state-owned vaccine manufacturer in Indonesia , has signed an agreement to develop a biosimilar to the monoclonal antibody ( mAb ) trastuzumab for cancer treatment that will be produced in Indonesia .
Kalbe Farma has also launched biosimilar version of insulin in Indonesia to treat diabetes mellitus which is 38 % cheaper than the existing insulin . Biosimilars are cheaper imitations of drugs known as biologics .
Kalbe Farma set up its biological drug factory , PT Kalbio Global Medika in Cikarang , Bekasi , with an investment value that ranges between USD 30 to USD 35 million . The factory is built under the joint venture between Kalbe and a South Korean pharmaceutical company Genexine Inc , PT Kalbe-Genexine Biologics
Key Topics Covered in the Report : Indonesia Dietary Vitamin Supplements Market Pharmaceutical Market Size Indonesia Indonesia Vaccine Market Indonesia Pharmaceutical Regulations Number of Pharmaceutical Companies Indonesia